Cleo Diagnostics Ltd (ASX:COV)

Market Cap	85.54M +87.5%
Revenue (ttm)	2.56M +1,115.5%
Net Income	-4.03M
EPS	-0.03
Shares Out	136.86M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	388,161
Average Volume	186,029
Open	0.6750
Previous Close	0.6250
Day's Range	0.6500 - 0.6900
52-Week Range	0.3150 - 0.9000
Beta	0.41
RSI	59.58
Earnings Date	May 26, 2026

About Cleo Diagnostics

Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2021
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: COV

Financial Performance

In fiscal year 2025, Cleo Diagnostics's revenue was 845,172, an increase of 300.91% compared to the previous year's 210,812. Losses were -4.00 million, 6.38% more than in 2024.